- For over eight decades, FDC Ltd has been a quiet force in Indian pharmaceuticals - the company that created the oral rehydration salts (ORS) category in India and still owns it with a brand, Electral, that commands more than 70% of the market. Founded in 1936 as a partnership and incorporated in 1940, it began with ophthalmic preparations and has since expanded into a fully integrated operation that makes its own active pharmaceutical ingredients (APIs), formulates them into finished medicines, and sells branded generics across more than 40 countries. The recurring pattern is backward integration - FDC consistently brings the production of key raw materials in-house, so its branded formulations rest on APIs it controls, which gives it cost certainty and supply security whether it is selling to a doctor in Mumbai or a global NGO in Africa.
Business segments
A single pharmaceutical engine with three reinforcing layers - branded generics sold to Indian doctors, export formulations supplied to regulated and institutional markets, and the API manufacturing backbone that feeds both - all produced across six accredited plants.
1. Domestic branded formulations: where the prescriptions and the market power sit
A field force of over 3,200 medical representatives details more than 300 products to general physicians and consultants, anchored by category-defining brands that hold number-one positions with market shares as high as 75%.
- Category creator in ORS - Electral, the company's flagship brand, pioneered the oral rehydration salts category in India and holds a 70.6% market share, making it the default prescription for dehydration and the first FDC brand to cross the ₹500 crore sales mark.
- Leader across multiple molecules - Zifi (Cefixime) leads its antibiotic category with a 25.4% share, while its combination Zifi CV commands 49.0% of the Cefixime-plus-Clavulanic acid market; Enerzal leads oral electrolytes at 49.9%, and Zocon leads Fluconazole at 30.0%.
- Deep physician reach, now hybrid - the sales force operates through 10 divisions and has been reorganised with Regional Manager zones to improve coverage in Tier 2 and Tier 3 towns, while a new CRM platform combines e-detailing, video consultations, and in-clinic visits with real-time analytics on secondary sales and inventory.
- Portfolio stretches from acute to chronic - the top 10 therapies contribute 88% of the company's Indian pharmaceutical market presence, with gastrointestinal care (24.8% growth in FY25), gynaecology (25.4%), and anti-diabetic (23.4%) among the fastest-growing segments, alongside a functional-foods division that includes infant milk substitutes like Simyl-MCT (rank 2 with 31.3% share) and ready-to-drink energy products.
- Bought as well as built - FDC made its first-ever brand acquisition in India by purchasing Enteroplus from GlaxoSmithKline, adding an adjunct gastrointestinal therapy that complements its anti-infective prescriptions.
2. International formulations: quality-led exports to regulated markets and global NGOs
The export business runs on the same plants that serve India, but targets niches - ophthalmic solutions, anti-infectives, and ORS - where FDC's manufacturing accreditations and in-house APIs give it a cost edge.
- The US is the largest destination - America accounts for roughly half of international revenue, and most commercial formulations sold there are vertically integrated with APIs from the USFDA-approved Roha plant, making the business highly profitable when regulatory approvals are current.
- ANDA approvals build the pipeline - the company has secured US approvals for Ofloxacin Otic Solution, Cefixime tablets and oral suspension, Pilocarpine Hydrochloride Ophthalmic Solution in three strengths, and Fluconazole Tablets in four strengths, steadily expanding the portfolio of products it can sell in the American market.
- The UK subsidiary doubles as a humanitarian supplier - FDC International Ltd, which grew 14% in FY25, was the first Indian company to introduce sterile ophthalmic products using Blow-Fill-Seal technology in the UK and supplies anti-diarrheal and ophthalmic products to UNICEF, IDA, MSF, and PSI.
3. Active pharmaceutical ingredients: the backward-integration backbone
FDC makes the key chemical ingredients for its own formulations and sells them to external customers, with a manufacturing history that stretches back to one of India's earliest USFDA accreditations.
- Two decades of in-house API production - the Roha facility received its first USFDA approval in 1985 and has been re-approved six consecutive times since, while the Waluj plant produces bulk APIs with a total capacity of 156 metric tonnes.
- Captive consumption drives the economics - the API business supplies the company's own formulation plants, particularly for the US export portfolio where vertical integration from API to finished dose is the source of profitability, and also sells to external customers in markets including Japan, Germany, Switzerland, Brazil, and South Korea.
- Regulatory filings keep markets open - FDC has filed 10 Certificate of Suitability applications, 17 new API Drug Master Files for its ophthalmic range, and updated four DMFs with the USFDA, while also responding successfully to European requirements on Nitrosamine impurity control for Fluconazole and Flurbiprofen.
Manufacturing and quality
Six plants, each with overlapping regulatory approvals from the USFDA, UK-MHRA, WHO-GMP, and others, produce everything from sterile eye drops to 125 million ORS sachets a month - and recent inspections have closed with zero observations.
- Waluj is the multi-format workhorse - it produces bulk APIs, one million oral liquid bottles, three million ophthalmic bottles, and 7.5 million ORS sachets per month, and holds approvals from the USFDA, WHO-GMP, ANVISA Brazil, EDQM, PMDA-Japan, and UK-MHRA, with the ophthalmic facility having undergone seven MHRA inspections since 2003.
- Sinnar is among the world's largest ORS plants - it can produce 125 million ORS sachets and 28 million food-powder sachets per month, exports to nearly all global markets, and is expanding its liquid oral capacity by 77,000 kilolitres per annum with a ₹140 crore investment funded from internal accruals.
- Baddi handles cephalosporins at scale - with capacity for 330 million tablets and 750,000 oral liquid bottles per month, it holds USFDA accreditation and underwent an inspection in August 2024 that closed with zero observations.
- Specialised technology is embedded in the lines - Blow-Fill-Seal machines produce ophthalmic bottles in a single sterile operation with no human intervention, Fluidized Bed Processors make sustained-release pellets in-house, and bi-layer tablet presses combine multiple drugs into one dose.
- Supply chain is being rewired - the company is building local supplier networks near its plants under a China-plus-one sourcing strategy, introducing Vendor Managed Inventory and Just-in-Time models for imported and packing materials, and digitising procurement with e-sourcing tools.
Research and development
Four in-house R&D teams - formulations, synthetics, nutraceuticals, and biotechnology - work on everything from complex ophthalmic gels to generic peptides and infant milk substitutes, with a growing patent portfolio.
- Synthetics R&D feeds the API pipeline - it develops processes for niche products in ophthalmic, antihypertensive, antifungal, anti-diabetic, and inhalation COPD areas, and works on New Chemical Entities alongside generic peptide molecules for leukoderma, osteoporosis, and diabetes.
- Biotechnology is a long-term bet - the Jogeshwari facility holds a test licence for manufacturing clinical-trial batches of Filgrastim (G-CSF), a third-generation thrombolytic (Reteplase) is under development with an external partner using the Pichia strain, and the company is evaluating Ranibizumab, a molecule for age-related macular degeneration that ties back to its ophthalmic heritage.
- Nutraceuticals R&D builds the consumer side - the team formulates sports drinks, infant milk substitutes across all four IMS categories, and health supplements, having developed products like Enerzal Blitz, Zefrich Advance with DHA, and immunity-boosting drinks.
Group structure and partners
Three wholly owned subsidiaries in the US, UK, and South Africa serve as local footholds for regulated and institutional markets, while the founding family retains nearly 70% ownership.
- FDC Inc., USA - the American subsidiary handles the largest export market, which accounts for roughly half of international revenue.
- FDC International Ltd, UK - the UK subsidiary operates a branch office, supplies anti-diarrheal and ophthalmic products to UNICEF, MSF, and WHO, and experienced a 65% YOY increase in FY24.
- Fair Deal Corporation Pharmaceutical SA, South Africa - originally a joint venture, FDC increased its stake to 93% in October 2020, making it a subsidiary that now serves as the head office for Southern Africa and recorded 53% growth in FY25.
- Promoter control - the founding Chandavarkar family held 69.36% of equity shares as of February 2022, with multiple generations in executive roles.